A Phase 3 interventional study of SOK583A1 (40 mg/mL) and Prefilled Syringe (PFS) in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz. Completed at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-11-18.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 52nd largest by enrollment, is one of 4 that started in 2022, is one of 18 in phase 3, and was the 51st registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 4 started in 2022.
This study's enrollment of 30 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 46th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2022, is one of 23 in phase 3, and was the 71st registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with nAMD, eligible for Intravitreal (IVT) aflibercept treatment.
Screening and Baseline could be performed on the same day.
Subjects with nAMD received a single dose of study treatment (2 mg SOK583 in 0.05 mL) in line with the Eylea US PI, which recommends a dose of 2 mg aflibercept (0.05 mL) administered by IVT injection. Only subjects already under IVT Eylea treatment and hence familiar with the IVT procedure were eligible for the study. Administration of the study treatment was embedded into their individual dosing schedule.
Demonstration of the safe use of the PFS containing SOK583A1 was based on the performance of at least 3 different ophthalmologist teams.
Follow-up visits were performed on-site on Day 8 (±2 days) and on Day 31 (+4 days - end of study visit). Subjects participated for 30 to 34 days in the study including Baseline and treatment on Day 1 (Screening and Baseline could be performed on the same day) and the last safety follow-up on Day 31 (a time window of plus 4 days was allowed for the last safety follow-up).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study
Drug: SOK583A1 (40 mg/mL) · Device: Prefilled Syringe (PFS)
Drug page: Aflibercept
SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
Also known as: aflibercept
Prefilled Syringe (PFS)
Number of Participants With Ocular Treatment Emergent Adverse Events
Number of participants with ocular treatment emergent adverse events were reported.
Time frame: throughout the study, approximately 31 days
Number of Participants With Non-ocular Treatment Emergent Adverse Events
Number of participants with non ocular Treatment emergent adverse events were reported.
Time frame: throughout the study, approximately 31 days
Study was conducted in 3 study sites in the US. All 3 sites screened and treated participants.
| Milestone | SOK583A1 (40 mg/mL) |
|---|---|
| Started | 30 |
| Full analysis set (fas) | 30 |
| Completed | 30 |
| Not completed | 0 |
Number of participants with ocular treatment emergent adverse events were reported.
| Participants | SOK583A1 (40 mg/mL) |
|---|---|
| Number of Participants With Ocular Treatment Emergent Adverse Events | 2 |
Number of participants with non ocular Treatment emergent adverse events were reported.
| Participants | SOK583A1 (40 mg/mL) |
|---|---|
| Number of Participants With Non-ocular Treatment Emergent Adverse Events | 1 |
Collected over Adverse events were collected throughout the study i.e. approximately 31 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOK583A1 (40 mg/mL) | 0/30 (0%) | 0/30 (0%) | 3/30 (10%) |
| Event | SOK583A1 (40 mg/mL) |
|---|---|
| Foreign body sensation in eyesEye disorders | 1/30 |
| Intraocular pressure increasedInvestigations | 1/30 |
| HypertensionVascular disorders | 1/30 |
| Ocular discomfortEye disorders | 1/30 |
| Age, Continuous(Years) | SOK583A1 (40 mg/mL) |
|---|---|
| Mean | 79.4 ± 7.41 |
| Sex: Female, Male(Participants) | SOK583A1 (40 mg/mL) |
|---|---|
| Female | 19 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | SOK583A1 (40 mg/mL) |
|---|---|
| White | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2022 to primary completion in May 2022, 1 month.
Results were first posted in Nov 2022, 6 months after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 1 month is below that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept